Overview

Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH

Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-armed, prospective single-centre clinical study to evaluate the effect of riociguat on right heart size and function in patients with manifest PAH and CTEPH.
Phase:
Phase 4
Details
Lead Sponsor:
Heidelberg University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Riociguat